Analysis Of Income And Expense [Abstract]

Zealand Pharma - Filing #1382857

Concept	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	103,986,000 EUR	108,546,000 EUR	192,001,000 EUR
Material income and expense [abstract]
Royalty expense	0 EUR	10,970,000 EUR	0 EUR
Research and development expense	614,044,000 EUR	581,511,000 EUR	595,847,000 EUR
Other operating income (expense)	57,587,000 EUR	2,173,000 EUR	0 EUR
Selling, general and administrative expense [abstract]
General and administrative expense	237,210,000 EUR	235,609,000 EUR	201,594,000 EUR
Operating expense	941,139,000 EUR	881,893,000 EUR	818,236,000 EUR
Sales and marketing expense	32,298,000 EUR	62,600,000 EUR	20,795,000 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	462,000 EUR	5,178,000 EUR	8,977,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	1,201,673,000 EUR	1,012,971,000 EUR	837,752,000 EUR